Bibliography
- Bendle GM , LinnemannC, HooijkaasAI et al.: Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.Nat. Med.16(5) , 565–570 (2010).
- Krensky AM , WeissA, CrabtreeG, DavisMM, ParhamP: T-lymphocyte-antigen interactions in transplant rejection.N. Engl. J. Med.322(8) , 510–517 (1990).
- Donohue JH , RosensteinM, ChangAE, LotzeMT, RobbRJ, RosenbergSA: The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.J. Immunol.132(4) , 2123–2128 (1984).
- Thomas DA , MassagueJ: TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.Cancer Cell8(5) , 369–380 (2005).
- Gorelik L , FlavellRA: Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells.Nat. Med.7(10) , 1118–1122 (2001).
- Heemskerk MH , HoogeboomM, HagedoornR, KesterMG, WillemzeR, FalkenburgJH: Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.J. Exp. Med.199(7) , 885–894 (2004).
- Weinhold M , SommermeyerD, UckertW, BlankensteinT: Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity.J. Immunol.179(8) , 5534–5542 (2007).
- Kuball J , DossettML, WolflM et al.: Facilitating matched pairing and expression of TCR chains introduced into human T cells.Blood109(6) , 2331–2338 (2007).
- Cohen CJ , LiYF, El-GamilM, RobbinsPF, RosenbergSA, MorganRA: Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.Cancer Res.67(8) , 3898–3903 (2007).
- De Felipe P , MartinV, CortesML, RyanM, IzquierdoM: Use of the 2a sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy.Gene Ther.6(2) , 198–208 (1999).
- Greenbaum BH : Transfusion-associated graft-versus-host disease: historical perspectives, incidence, and current use of irradiated blood products.J. Clin. Oncol.9(10) , 1889–1902 (1991).
- Schroeder ML : Transfusion-associated graft-versus-host disease.Br. J. Haematol.117(2) , 275–287 (2002).
- Agbaht K , AltintasND, TopeliA, GokozO, OzcebeO: Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature.Transfusion47(8) , 1405–1411 (2007).
- Morgan RA , DudleyME, WunderlichJR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes.Science314(5796) , 126–129 (2006).
- Johnson LA , MorganRA, DudleyME et al.: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood114(3) , 535–546 (2009).
- Kolen S , DolstraH, Van De Locht L et al.: Biodistribution and retention time of retrovirally labeled T lymphocytes in mice is strongly influenced by the culture period before infusion. J. Immunother.25(5) , 385–395 (2002).
- Gattinoni L , KlebanoffCA, PalmerDC et al.: Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.J. Clin. Invest.115(6) , 1616–1626 (2005).
- Zhou J , ShenX, HuangJ, HodesRJ, RosenbergSA, RobbinsPF: Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.J. Immunol.175(10) , 7046–7052 (2005).
- Dotti G , SavoldoB, BrennerM: Fifteen years of gene therapy based on chimeric antigen receptors: ‘are we nearly there yet?‘Hum. Gene Ther.20(11) , 1229–1239 (2009).
- Pule MA , SavoldoB, MyersGD et al.: Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.Nat. Med.14(11) , 1264–1270 (2008).
- Ciceri F , BoniniC, StanghelliniMT et al.: Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised Phase I–II study.Lancet Oncol.10(5) , 489–500 (2009).
- Hoyos V , SavoldoB, QuintarelliC et al.: Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.Leukemia24(6) , 1160–1170 (2010).
- Rosenberg SA , RestifoNP, YangJC, MorganRA, DudleyME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy.Nat. Rev. Cancer8(4) , 299–308 (2008).